Pharmacological significance of glycosylation in therapeutic proteins

Current Opinion in Biotechnology

Volumn 20, Issue 6, 2009, Pages 678-684

  Li, Huijuan ^a   d'Anjou, Marc ^a  

^a GlycoFi Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPHARMACEUTICALS; CLINICAL DEVELOPMENT; ILLUSTRATIVE EXAMPLES; IMMUNOGENICITY; N-LINKED; O-LINKED; RECOMBINANT GLYCOPROTEINS; THERAPEUTIC PROTEIN;

CARBOHYDRATES; ESTERIFICATION; GLYCOPROTEINS; GLYCOSYLATION;

PROTEINS;

ALEFACEPT; ALPHA DYSTROGLYCAN; B CELL ACTIVATING FACTOR RECEPTOR; CARBOHYDRATE; CETUXIMAB; FC RECEPTOR; FOLLITROPIN; GLYCOPROTEIN; IMMUNOGLOBULIN G; LENERCEPT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB;

ADAPTIVE IMMUNITY; ANEMIA; ANOVULATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOLOGICAL THERAPY; CARBOHYDRATE ANALYSIS; CELL LINE; CHO CELL; COLORECTAL CARCINOMA; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; GENETIC MANIPULATION; GLYCOSYLATION; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW;

ANIMALS; BIOLOGICAL PRODUCTS; BIOPHARMACEUTICS; BIOTECHNOLOGY; CARBOHYDRATES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; IMMUNE SYSTEM; PROTEIN BINDING; PROTEINS; RECOMBINANT PROTEINS;

EID: 70449732650     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2009.10.009     Document Type: Review

References (66)

1. Helenius A., and Aebi M. Intracellular functions of N-glycans. Science 291 (2001) 2364-2369
2. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., Murphy B.A., Satinover S.M., Hosen J., Mauro D., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 (2008) 1109-1117. The paper described that most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
3. Sinclair A.M., and Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94 (2005) 1626-1635
4. Butler M. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems. Cytotechnology 50 (2006) 57-76
5. Hossler P., Khattak S.F., and Li Z.J. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19 (2009) 936-949
6. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87 (2004) 614-622
7. Davies J., Jiang L., Pan L.Z., LaBarre M.J., Anderson D., and Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for Fc gamma RIII. Biotechnol Bioeng 74 (2001) 288-294
8. Li H., Sethuraman N., Stadheim T.A., Zha D., Prinz B., Ballew N., Bobrowicz P., Choi B.K., Cook W.J., Cukan M., et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24 (2006) 210-215. This report describes the expression of IgG1 with human N-glycosylation in yeast. IgG1 antibodies produced by this expression system demonstrate >100-fold enhanced receptor binding and increased in vitro B-cell depletion activity compared with a matched CHO-produced IgG1.
9. Hamilton S.R., Davidson R.C., Sethuraman N., Nett J.H., Jiang Y., Rios S., Bobrowicz P., Stadheim T.A., Li H., Choi B.K., et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (2006) 1441-1443. The first demonstration of the production of protein in yeast harboring human complex glycosylation with greater than 90% terminal sialylation is described. Functional recombinant erythropoietin was produced from the reported cell line.
10. Wildt S., and Gerngross T.U. The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 3 (2005) 119-128
11. Gerngross T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22 (2004) 1409-1414
12. Sethuraman N., and Stadheim T.A. Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17 (2006) 341-346
13. Choi B.K., Bobrowicz P., Davidson R.C., Hamilton S.R., Kung D.H., Li H., Miele R.G., Nett J.H., Wildt S., and Gerngross T.U. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci U S A 100 (2003) 5022-5027. Production of a glycoprotein with human hybrid N-glycosylation in yeast is described. A high-throughput screening method for the selection of yeast clones with uniform hybrid N-glycosylation is described.
14. Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T., Nett J.H., Rausch S., Stadheim T.A., Wischnewski H., et al. Production of complex human glycoproteins in yeast. Science 301 (2003) 1244-1246. The first demonstration of the production of protein in yeast harboring human complex N-glycosylation is described. Human N-glycosylation pathway engineering expands the role of yeast for the production of therapeutic glycoproteins.
15. Bobrowicz P., Davidson R.C., Li H., Potgieter T.I., Nett J.H., Hamilton S.R., Stadheim T.A., Miele R.G., Bobrowicz B., Mitchell T., et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 14 (2004) 757-766
16. Potgieter T.I., Cukan M., Drummond J.E., Houston-Cummings N.R., Jiang Y., Li F., Lynaugh H., Mallem M., McKelvey T.W., Mitchell T., et al. Production of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 139 (2009) 318-325
17. Hamilton S.R., and Gerngross T.U. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 18 (2007) 387-392
18. Chiba Y., and Akeboshi H. Glycan engineering and production of 'humanized' glycoprotein in yeast cells. Biol Pharm Bull 32 (2009) 786-795
19. Burda P., and Aebi M. The dolichol pathway of N-linked glycosylation. Biochim Biophys Acta 1426 (1999) 239-257
20. Knauer R., and Lehle L. The oligosaccharyltransferase complex from yeast. Biochim Biophys Acta 1426 (1999) 259-273
21. Herscovics A. Processing glycosidases of Saccharomyces cerevisiae. Biochim Biophys Acta 1426 (1999) 275-285
22. Kornfeld R., and Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54 (1985) 631-664
23. Baenziger J.U., and Green E.D. Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochim Biophys Acta 947 (1988) 287-306
24. Rudd P.M., Elliott T., Cresswell P., Wilson I.A., and Dwek R.A. Glycosylation and the immune system. Science 291 (2001) 2370-2376
25. Middleton J., Patterson A.M., Gardner L., Schmutz C., and Ashton B.A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100 (2002) 3853-3860
26. Fears C.Y., and Woods A. The role of syndecans in disease and wound healing. Matrix Biol 25 (2006) 443-456
27. Ernst J.F., Mermod J.J., and Richman L.H. Site-specific O-glycosylation of human granulocyte/macrophage colony-stimulating factor secreted by yeast and animal cells. Eur J Biochem/FEBS 203 (1992) 663-667
28. Muller S., and Hanisch F.G. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J Biol Chem 277 (2002) 26103-26112
29. Sewell R., Bäckström M., Dalziel M., Gschmeissner S., Karlsson H., Noll T., Gätgens J., Clausen H., Hansson G.C., Burchell J., et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 281 (2006) 3586-3594
30. Endo T. O-Mannosyl glycans in mammals. Biochim Biophys Acta 1473 (1999) 237-246
31. Barresi R., and Campbell K.P. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 119 (2006) 199-207
32. Muntoni F., Brockington M., Blake D.J., Torelli S., and Brown S.C. Defective glycosylation in muscular dystrophy. Lancet 360 (2002) 1419-1421
33. Takeuchi M., Inoue N., Strickland T.W., Kubota M., Wada M., Shimizu R., Hoshi S., Kozutsumi H., Takasaki S., and Kobata A. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 86 (1989) 7819-7822
34. Misaizu T., Matsuki S., Strickland T.W., Takeuchi M., Kobata A., and Takasaki S. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 86 (1995) 4097-4104
35. Darling R.J., Kuchibhotla U., Glaesner W., Micanovic R., Witcher D.R., and Beals J.M. Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. Biochemistry 41 (2002) 14524-14531
36. Elliott S., Egrie J., Browne J., Lorenzini T., Busse L., Rogers N., and Ponting I. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32 (2004) 1146-1155
37. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20 (2008) 460-470
38. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., Goetsch L., Wurch T., Van Dorsselaer A., and Corvaïa N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 9 (2008) 482-501
39. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30 (2009) 356-362
40. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8 (2009) 226-234
41. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcg RIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002) 26733-26740
42. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
43. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003) 3466-3473
44. Zhou Q., Shankara S., Roy A., Qiu H., Estes S., McVie-Wylie A., Culm-Merdek K., Park A., Pan C., and Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99 (2008) 652-665. This paper described that antibodies expressed in the presence of kifunensine contain mainly oligomannose-type glycans with increased ADCC activity and affinity for FcγRIIIA, but reduced C1q binding. It also described that the serum levels of antibody in mice were not significantly altered up to 168 hours following injection.
45. Peipp M., Lammerts van Bueren J.J., Schneider-Merck T., Bleeker W.W., Dechant M., Beyer T., Repp R., van Berkel P.H., Vink T., van de Winkel J.G., et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112 (2008) 2390-2399. It was demonstrated for the first time that lack of fucose does not generally increase the ADCC activity of therapeutic antibodies and that the impact of Fc glycosylation on ADCC is critically dependent on the recruited effector cell type.
46. Shibata-Koyama M., Iida S., Misaka H., Mori K., Yano K., Shitara K., and Satoh M. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 37 (2009) 309-321. It was demonstrated that antibody therapy composed of nonfucosylated rituximab can activate human neutrophil functions involving phagocytosis and MHC class II expression, which may favorably potentiate the adaptive immune response in cancer patients.
47. Shibata-Koyama M., Iida S., Okazaki A., Mori K., Kitajima-Miyama K., Saitou S., Kakita S., Kanda Y., Shitara K., Kato K., et al. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 19 (2009) 126-134. The paper described that N-45 is an inhibitory element for the high Fc gamma RIIIa binding affinity mediated by N-162 to nonfucosylated antibodies.
48. LaPolt P.S., Nishimori K., Fares F.A., Perlas E., Boime I., and Hsueh A.J. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology 131 (1992) 2514-2520
49. Fares F.A., Suganuma N., Nishimori K., LaPolt P.S., Hsueh A.J., and Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A 89 (1992) 4304-4308
50. Perlman S., van den Hazel B., Christiansen J., Gram-Nielsen S., Jeppesen C.B., Andersen K.V., Halkier T., Okkels S., and Schambye H.T. Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrinol Metab 88 (2003) 3227-3235
51. Klein J., Lobel L., Pollak S., Lustbader B., Ogden R.T., Sauer M.V., and Lustbader J.W.J. Development and characterization of a long-acting recombinant hFSH agonist. Hum Reprod 18 (2003) 50-56
52. Weenen C., Peña J.E., Pollak S.V., Klein J., Lobel L., Trousdale R.K., Palmer S., Lustbader E.G., Ogden R.T., and Lustbader J.W. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. J Clin Endocrinol Metab 89 (2004) 5204-5212
53. Devroey P., Fauser B.C., Platteau P., Beckers N.G., Dhont M., and Mannaerts B.M. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 89 (2004) 2062-2070
54. Ruman J.I., Pollak S., Trousdale R.K., Klein J., and Lustbader J.W. Effects of long-acting recombinant human follicle-stimulating hormone analogs containing N-linked glycosylation on murine folliculogenesis. Fertility Sterility 83 Suppl 1 (2005) 1303-1309
55. Keck R., Nayak N., Lerner L., Raju S., Ma S., Schreitmueller T., Chamow S., Moorhouse K., Kotts C., and Jones A. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 36 (2008) 49-60. The paper described that the pharmacokinetic variability correlated with terminal N-acetylglucosamine and not with terminal galactose, sialic acid, or any polypeptide related parameter.
56. Meier W., Gill A., Rogge M., Dabora R., Majeau G.R., Oleson F.B., Jones W.E., Frazier D., Miatkowski K., and Hochman P.S. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 2 (1995) 159-171
57. Stork R., Zettlitz K.A., Müller D., Rether M., Hanisch F.G., and Kontermann R.E. N glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 283 (2008) 7804-7812
58. Marinaro J.A., Casley D.J., and Bach L.A. O-Glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. Eur J Endocrinol 142 (2000) 512-516
59. Stefanich E.G., Ren S., Danilenko D.M., Lim A., Song A., Iyer S., and Fielder P.J. Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins. J Pharmacol Exp Ther 327 (2008) 308-315. The paper presented data to suggest that exposed Gal on the desialylated BR3-Fc O-glycosylation led to rapid clearance due to uptake and degradation in the liver that was associated with nonparenchymal cells while the exposed GalNAc did not seem to play a role in the clearance of BR3-Fc.
60. Huang L., Biolsi S., Bales K.R., and Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem 349 (2006) 197-207. The data described in the paper showed that there is no strong correlation between oligosaccharide structures in the Fv region and their clearance rates in vivo. It was shown that biantennary oligosaccharides lacking galactosylation had slightly faster clearance rates than other structures in the Fv domain.
61. Gribben J.G., Devereux S., Thomas N.S., Keim M., Jones H.M., Goldstone A.H., and Linch D.C. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335 (1990) 434-437
62. Bork K., Horstkorte R., and Weidemann W. Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J Pharm Sci 98 (2009) 3499-3508
63. Bardor M., Faveeuw C., Fitchette A.C., Gilbert D., Galas L., Trottein F., Faye L., and Lerouge P. Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. Glycobiology 13 (2003) 427-434
64. Jin C., Altmann F., Strasser R., Mach L., Schähs M., Kunert R., Rademacher T., Glössl J., and Steinkellner H. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology 18 (2008) 235-241. The paper provided evidence for the adverse potential of nonmammalian N-glycan modifications present on monoclonal antibodies produced in plants.
65. Thobhani S., Yuen C.T., Bailey M.J., and Jones C. Identification and quantification of N-linked oligosaccharides released from glycoproteins: an inter-laboratory study. Glycobiology 19 (2009) 201-211. The study highlighted the need for well-characterized reference standards to support method validation and regulatory guidance on the selection of glycosylation analysis.
66. Rich J.R., and Withers S.G. Emerging methods for the production of homogeneous human glycoproteins. Nat Chem Biol 5 (2009) 508-514